Publications

April 2001 (Revised January 2003)
Case

Robert Shapiro and Monsanto

Traces Monsanto's efforts to become a global biotech powerhouse under Shapiro's leadership. Examines how his crusade to save the world through genetic modification foundered. View Details

Keywords: Genetics; Supply Chain Management; Alliances; Global Strategy; Cross-Cultural and Cross-Border Issues; Biotechnology Industry

December 2000
Case

Paradigm Genetics: The Industrialization of Genomics

By: Ray A. Goldberg, Carin-Isabel Knoop and Laure Mougeot Stroock

Keywords: Genetics; Biotechnology Industry

Find at Harvard

November 1999
Case

Seminis Inc.

By: Ray A. Goldberg, Jonathan West, Carin-Isabel Knoop and David Benedict Pearcy

Seminis became the world leader in vegetable seeds through a series of acquisitions. This case describes the Seminis strategy toward capturing value, biotechnology, and international operations. View Details

Keywords: Business Earnings; Acquisition; Profit; Global Strategy; Corporate Strategy; Valuation; Value Creation; Biotechnology Industry

Find at Harvard

August 1996 (Revised May 1997)
Case

Delta & Pine Land: Measuring the Value of Transgenic Cotton

By: Ray A. Goldberg and Charlotte A. Tasker

Discusses the joint venture between two companies with different capabilities: 1) technology provider and 2) transportation agent. Discusses how to capture value from joint venture and biotechnology: 1) who are winners and who are losers; 2) how much value can/should... View Details

Keywords: Agribusiness; Joint Ventures; Marketing Strategy; Supply Chain Management; Performance Consistency; Information Technology; Transportation; Valuation; Biotechnology Industry

November 1995 (Revised February 1996)
Case

Monsanto Company: The Coming of Age of Bio-Technology

By: Ray A. Goldberg and Thomas N. Urban Jr

Monsanto has one product, Roundup, accounting for 30% of company net income and is going off patent. How should the company position itself and its products in the future? View Details

Keywords: Patents; Product Positioning; Strategic Planning; System Shocks; Biotechnology Industry

November 1978 (Revised October 1989)
Case

Amicon Corp. (B)

Details the negotiation between Amicon and three potential licensees, Jackson, Maynard-Smith and Behrstein. View Details

Keywords: Technology; Patents; Negotiation Process; Negotiation Participants; Health Care and Treatment; Biotechnology Industry

02 Feb 2021
Blog Post

Finding My Focus in Health care Amidst a Global Pandemic

biotechnology and health-tech companies. After about a year and a half, I went to work at one of JPM’s clients to build their Growth Strategy team. After an interesting first several months, I found myself testifying as a whistleblower to... View Details

September 2024
Case

Myeloma Investment Fund

By: Kyle Myers and Scott Sawaya

This case explores a critical decision facing the Myeloma Investment Fund (MIF) as it evaluates two investment opportunities aimed at accelerating a cure for multiple myeloma.

The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details

Keywords: Venture Philanthropy; Biomedical Research; Investing For Impact; Innovation ＆ Entrepreneurship; Venture Capital; Science-Based Business; Philanthropy and Charitable Giving; Decision Making; Health Care and Treatment; Biotechnology Industry; Biotechnology Industry

November 2014
Teaching Note

Claritas Genomics

By: Robert F. Higgins and Matthew G. Preble

Dr. Patrice Milos is the first CEO of Claritas Genomics (Claritas) and she faces a number of challenges in scaling the young company. Claritas was formed around a lab spun out from Boston Children's Hospital (BCH) which had performed genomic tests for the hospital. Now... View Details

Keywords: Healthcare; Healthcare Startups; Genetic Testing; Genetics Diagnostics; Spinning Out Hospital Services; Spin-out; Health Care and Treatment; Genetics; Entrepreneurship; Biotechnology Industry; Biotechnology Industry; United States

September 2014
Case

Pfizer's Centers for Therapeutic Innovation (CTI)

By: Gary Pisano, James Weber and Kait Szydlowski

In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration... View Details

Keywords: Drug Development; Academic Collaboration; Research And Development; Innovation; Translational Research; Management; Operations; Problems and Challenges; Research; Science; Information Technology; Strategy; Biotechnology Industry; Biotechnology Industry; North and Central America; Europe; Asia

June 2013
Supplement

Can PACIV (Puerto Rico) Serve European Customers? (Video Supplement)

By: Jim Sharpe

This is Video Supplement for Can PACIV (Puerto Rico) Serve European Customers? HBS Case #808099. View Details

December 2010
Teaching Note

Roche's Acquisition of Genentech (TN)

By: Bo Becker and Carliss Y. Baldwin

Teaching Note for 210-040. View Details

Keywords: Mergers and Acquisitions; Stock Shares; Opportunities; Strategy; Organizational Culture; Value; Negotiation Tactics; Biotechnology Industry; Biotechnology Industry

11 Oct 2009
Conference Presentation

The impact of institutional actors as attention structures on entrepreneurial activity in the U.S. biodiesel industry

By: Shon R. Hiatt

Keywords: Entrepreneurship; Biotechnology Industry; Biotechnology Industry; United States

November 2009
Case

The Explosion of Genetic Testing: Opportunities and Challenges

By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon

This case study invites the reader to consider genetic testing in several different lights. First, can the business of genetic testing be considered a disruptive innovation to the current drug therapy model as defined by Harvard Business School Professor Clay... View Details

Keywords: Genetics; Health Care and Treatment; Health Testing and Trials; Disruptive Innovation; Business Model; Biotechnology Industry; Biotechnology Industry

October 2009 (Revised July 2013)
Case

Gilead Sciences, Inc.: Access Program

By: V. Kasturi Rangan and Katharine Lee

Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients... View Details

Keywords: Health Care and Treatment; Emerging Markets; Product; Sales; Competitive Strategy; Biotechnology Industry; Biotechnology Industry

June 2008
Case

Gordon Williams: Clinical Research at Brigham and Women's Hospital

By: H. Kent Bowen and Courtney Purrington

Clinical research is a critical element of biomedical research and development. This case describes the challenges of clinical research, and its role in bringing breakthroughs to patients. Dr. Williams leads through his own research and special programs to train... View Details

Keywords: Training; Health Care and Treatment; Success; Programs; Research and Development; Biotechnology Industry; Biotechnology Industry

Find at Harvard

June 2003 (Revised October 2004)
Case

Novartis: The Challenge of Success (D)

By: Sandra J. Sucher and Stacy McManus

Supplements the (A) and (B) cases. View Details

Keywords: Biotechnology Industry; Biotechnology Industry

July 1993
Case

Genzyme Corporation: A Financing History

By: Timothy A. Luehrman and Andrew D. Regan

Genzyme Corp.'s financing history is unusual compared to most biotech companies. This case presents the sequence of financings employed by Genzyme, along with the product--market and corporate-development strategies adopted by Henri Termeer, Genzyme's CEO. As such, the... View Details

Keywords: History; Marketing Strategy; Financing and Loans; Business Strategy; Growth and Development Strategy; Biotechnology Industry

July 2023
Case

Moderna: Everything, Everywhere, All at Once

By: Satish Tadikonda, Shikhar Ghosh and William Marks

Coming out of the COVID-19 pandemic, Moderna was riding the successes of developing a vaccine in record time and helping stem the tide of the crisis. However, the company had grown at an incredible rate, more than doubled its number of employees, and had to put on hold... View Details

Keywords: Health Pandemics; Selection and Staffing; Growth Management; Management Succession; Retirement; Technological Innovation; Corporate Strategy; Biotechnology Industry